Spots Global Cancer Trial Database for Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)
Official Title: A Multicenter, NI, Retrospective, Observational Study Evaluating Real-World Treatment Outcomes in Japanese Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Avelumab Plus Axitinib as First-line Therapy: J-DART2
Study ID: NCT05650164
Conditions
Study Description
Brief Summary: This study is a multicenter, non-interventional, retrospective, medical chart review of patients with metastatic renal cell cancer(mRCC) treated with avelumab plus axitinib as a first-line therapy in Japan between 20 December 2019 and 17 October 2022. All decisions regarding clinical management and treatment of the participating patients were made by the investigator as part of standard care in real-world clinical setting and were not contingent upon the patient's participation in the study. Data will be collected if available per study site.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Nagoya University Hospital, Nagoya, Aichi, Japan
Hirosaki University Hospital, Hirosaki, Aomori, Japan
Kurume University Hospital, Kurume-shi, Fukuoka, Japan
Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan
Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan
Kobe City Medical Center General Hospital, Kobe-city, Hyogo, Japan
Kobe University Hospital, Kobe, Hyogo, Japan
Kanazawa University Hospital, Kanazawa-shi, Ishikawa, Japan
National Hospital Organization Kyoto Medical Center, Kyoto-shi, Kyoto, Japan
Kochi Medical School Hospital, Nankoku, Kōchi, Japan
Kindai University Hospital, Osakasayama, Osaka, Japan
Osaka University Hospital, Suita-city, Osaka, Japan
Jichi Medical University Saitama Medical Center, Saitama City, Saitama, Japan
Keio University Hospital, Shinjuku-ku, Tokyo, Japan
Wakayama Medical University Hospital, Wakayama-shi, Wakayama, Japan
Yamagata University Hospital, Yamagata-Shi, Yamagata, Japan
Kyushu University Hospital, Fukuoka, , Japan
Hiroshima University Hospital, Hiroshima, , Japan
University Hospital Kyoto Prefectural University of Medicine, Kyoto, , Japan
Contact Details
Name: Medical Responsible
Affiliation: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
